NLRP3 and diabetic kidney disease: Here, inhibition of BTK with ibrutinib reduced both NF‐κB and NLRP3 inflammasome activation in the kidney, reduced classical histological markers of early diabetic nephropathy, and protected mice from the development of proteinuria.